OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone(510) 775-0515
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.01. View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
What price target have analysts set for OCX?
5 equities research analysts have issued 12-month price targets for OncoCyte's stock. Their predictions range from $6.00 to $8.00. On average, they anticipate OncoCyte's stock price to reach $7.00 in the next year. This suggests a possible upside of 90.2% from the stock's current price. View Analyst Price Targets for OncoCyte.
What is the consensus analysts' recommendation for OncoCyte?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.
Has OncoCyte been receiving favorable news coverage?
News coverage about OCX stock has trended somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. OncoCyte earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for OncoCyte.
Are investors shorting OncoCyte?
OncoCyte saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 828,304 shares, an increase of 6.1% from the April 15th total of 780,426 shares. Based on an average daily volume of 126,270 shares, the days-to-cover ratio is presently 6.6 days. Approximately 2.8% of the company's shares are sold short. View OncoCyte's Current Options Chain.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include Mesoblast (MSB), Resverlogix (RVX), Theratechnologies (TH), Oxford BioMedica (OXB), Starpharma (SPL), Neptune Wellness Solutions (NEPT), Biotest (BIO), Kodiak Sciences (KOD), Emerald Health Therapeutics (EMH), Senesco Technologies (ELOX), Monash IVF Group (MVF), BELLUS Health (BLU), Rafael (RFL), Paradigm Biopharmaceuticals (PAR) and Emblem (EMC).
What other stocks do shareholders of OncoCyte own?
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett, Pres, CEO & Director (Age 65)
- Mr. Mitchell S. Levine, Chief Financial Officer
- Dr. Lyndal K. Hesterberg, Chief Scientific Officer
- Mr. Albert P. Parker II, Chief Operating Officer
- Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)
Who are OncoCyte's major shareholders?
OncoCyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.79%), Schonfeld Strategic Advisors LLC (1.67%), Renaissance Technologies LLC (0.26%), BlackRock Inc. (0.24%), Northern Trust Corp (0.11%) and JPMorgan Chase & Co. (0.09%). View Institutional Ownership Trends for OncoCyte.
Which institutional investors are buying OncoCyte stock?
OCX stock was acquired by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Spark Investment Management LLC and Virtu Financial LLC. View Insider Buying and Selling for OncoCyte.
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $3.68.
How big of a company is OncoCyte?
What is OncoCyte's official website?
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.
MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
